ArticleThe Journal of antimicrobial chemotherapy2018
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.
Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04903847 (Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2), which is not on this map. Cited by 101 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2
Who cites it
101 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Weight gain, obesity, and the impact of lifestyle factors among people living with HIV: A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Prevalence of obesity, hypertension and diabetes among people living with HIV in South Africa: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Guideline
- Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial.AIDS (London, England) · 2026Trial
- Comparison of central obesity prevalence among adults living with and without HIV in Botswana: a cross-sectional study.BMJ open · 2025Trial
- Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.AIDS research and therapy · 2025Trial
- Trial
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study.EClinicalMedicine · 2026Article
- Body Mass Index and Vaccine-induced Immune Responses in Children Living With HIV.The Pediatric infectious disease journal · 2026Article
- Longitudinal Serum Metabolomic Signatures Related to Integrase Strand Transfer Inhibitors-Associated Weight Gain in Women with HIV Enrolled in the MACS/WIHS Combined Cohort Study.The Journal of infectious diseases · 2026Article
- Assessment of Sarcopenia and Metabolic Abnormalities in HIV Patients Stable on Antiretroviral Therapy: A Cross-Sectional Analysis of an Indian Cohort.Journal of frailty, sarcopenia and falls · 2026Article
- Exploring the impact of Cabotegravir-Rilpivirine long-acting on weight gain, body composition and quality of life in adults living with HIV.HIV medicine · 2026Article
- Article
- Prevalence and associated factors of overweight and obesity among people living with HIV on antiretroviral therapy in a national hospital in Benin.Scientific reports · 2025Article
- The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review.Biochemistry and biophysics reports · 2025Review
- Decreased intestinal abundance ofAnnals of medicine · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on ART remain unclear. Objectives: In a cohort of HIV-infected adults in Rio de Janeiro, Brazil, we aimed to determine obesity rates before and after ART initiation and to analyse risk factors for obesity on ART. Methods: We retrospectively analysed data from individuals initiating ART between 2000 and 2015. BMI was calculated at baseline (time of ART initiation). Participants who were non-obese at baseline and had ≥90 days of ART exposure were followed until the development of obesity or the end of follow-up. Obesity incidence rates were estimated using Poisson regression models and risk factors were assessed using Cox regression models. Results: Of participants analysed at baseline (n = 1794), 61.3% were male, 48.3% were white and 7.9% were obese. Among participants followed longitudinally (n = 1567), 66.2% primarily used an NNRTI, 32.9% a PI and 0.9% an integrase strand transfer inhibitor (INSTI); 18.3% developed obesity and obesity incidence was 37.4 per 1000 person-years. In multivariable analysis, the greatest risk factor for developing obesity was the use of an INSTI as the primary ART core drug (adjusted HR 7.12, P < 0.0001); other risk factors included younger age, female sex, higher baseline BMI, lower baseline CD4+ T lymphocyte count, higher baseline HIV-1 RNA, hypertension and diabetes mellitus. Conclusions: Obesity following ART initiation is frequent among HIV-infected adults. Key risk factors include female sex, HIV disease severity and INSTI use. Further research regarding the association between INSTIs and the development of obesity is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.